These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37788604)

  • 21. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes.
    DeWeese JP; Krenz JR; Wakeman SE; Peckham AM
    Subst Abus; 2021; 42(4):506-511. PubMed ID: 33945452
    [No Abstract]   [Full Text] [Related]  

  • 23. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-Dose Initiation of Buprenorphine: A Narrative Review.
    Edinoff AN; Fahmy OH; Spillers NJ; Zaheri AR; Jackson ED; De Witt AJ; Wenger DM; Cornett EM; Skidmore KL; Kaye AM; Kaye AD
    Curr Pain Headache Rep; 2023 Jul; 27(7):175-181. PubMed ID: 37083890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine Inductions via Transdermal Patches for Opioid Use Disorder in the Inpatient Setting.
    Porras H; Johnson E; Kotova M; Chenoweth J; Colby D
    J Pain Palliat Care Pharmacother; 2023 Sep; 37(3):251-256. PubMed ID: 37326470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Community based buprenorphine micro-induction in the context of methadone maintenance treatment and fentanyl - Case report.
    Kaliamurthy S; Jegede O; Hermes G
    J Addict Dis; 2023; 41(2):175-180. PubMed ID: 35377273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
    Terasaki D; Smith C; Calcaterra SL
    Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.
    Callan J; Pytell J; Ross J; Rastegar DA
    J Addict Med; 2020; 14(5):e274-e276. PubMed ID: 31977358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.
    K K A; E J M; D M S
    Addict Sci Clin Pract; 2022 Oct; 17(1):55. PubMed ID: 36195895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.
    Spreen LA; Dittmar EN; Quirk KC; Smith MA
    Pharmacotherapy; 2022 May; 42(5):411-427. PubMed ID: 35302671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.
    Tang VM; Lam-Shang-Leen J; Brothers TD; Hansen K; Caudarella A; Lamba W; Guimond T
    Am J Addict; 2020 Jan; 29(1):73-76. PubMed ID: 31626394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine for treating cancer pain.
    Schmidt-Hansen M; Bromham N; Taubert M; Arnold S; Hilgart JS
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009596. PubMed ID: 25826743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.
    Chambers LC; Hallowell BD; Zullo AR; Paiva TJ; Berk J; Gaither R; Hampson AJ; Beaudoin FL; Wightman RS
    JAMA Netw Open; 2023 Sep; 6(9):e2334540. PubMed ID: 37721749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2001 Jun; 96(6):823-34. PubMed ID: 11399214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach.
    Vytialingam RC; Schug SA; O'Regan R
    J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities.
    Anderson C; Cooley R; Patil D
    J Addict Med; 2023 Mar-Apr 01; 17(2):241-244. PubMed ID: 36161824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.